CVS Health is trading sharply higher Tuesday after it lifted its full-year earnings and revenue outlook, sparking broad buying interest in the name and driving a roughly 3% premarket gain that has carried into the session. The guidance increase is the primary fresh, same-day catalyst for the stock’s approximately +3.85% move.

A higher outlook matters because CVS has been in a multi-part reset—re-pricing risk in its insurance business, working through medical cost pressures, and trying to re-accelerate earnings power across its integrated model. When guidance moves up, it signals that either utilization trends, pricing actions, expense controls, or operating performance are tracking better than the market had been discounting, which can quickly re-rate a beaten-down large-cap healthcare name.

Investors will be looking for follow-through: confirmation that medical cost trend assumptions remain stable, that pharmacy and services performance is durable, and that any regulatory overhangs around PBM practices do not re-intensify. The next major check is the company’s upcoming quarterly update and any incremental detail on segment-level drivers that supported the higher full-year view.